SELLAS Life Sciences GroupSLS -5.52%25 EV-to-EBITDA is -76.37 as of Jul. 11, 2026. GuruFocus rates SLS with a GF Score™ of 25/100. The stock has 1 warning sign investors should review. Among 392 Biotechnology companies, SELLAS Life Sciences Group ranks worse than 255101.79% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, SELLAS Life Sciences Group's enterprise value is $2,402.81 Mil.
SELLAS Life Sciences Group's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $-31.46 Mil. Therefore, SELLAS Life Sciences Group's EV-to-EBITDA for today is -76.37.
The historical rank and industry rank for SELLAS Life Sciences Group's EV-to-EBITDA or its related term are showing as below:
SLS'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -81.06 Med: -0.7 Max: 0.18
Current: -76.37
During the past 13 years, the highest EV-to-EBITDA of SELLAS Life Sciences Group was 0.18. The lowest was -81.06. And the median was -0.70.
SLS's EV-to-EBITDA is ranked worse than 100% of 392
companies
in the Biotechnology industry
Industry Median: 12.935
vs SLS: -76.37
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
SELLAS Life Sciences Group (NAS:SLS) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
SELLAS Life Sciences Group's PE Ratio (TTM) for today is calculated as:
SELLAS Life Sciences Group's share price for today is $12.76.
SELLAS Life Sciences Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.230.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, SELLAS Life Sciences Group's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SELLAS Life Sciences Group EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, SELLAS Life Sciences Group's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where SELLAS Life Sciences Group's EV-to-EBITDA falls into.
SELLAS Life Sciences Group's current Enterprise Value is $2,402.81 Mil.
SELLAS Life Sciences Group's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-31.46 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SELLAS Life Sciences Group (SLS) has a EV-to-EBITDA of -76.37 as of Jul. 11, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on SELLAS Life Sciences Group. According to the industry distribution chart, SELLAS Life Sciences Group ranks #999999 out of 392 companies in the Biotechnology industry.
Is SELLAS Life Sciences Group's EV-to-EBITDA too high?
SELLAS Life Sciences Group's current EV-to-EBITDA is -76.37. Based on the distribution chart, SELLAS Life Sciences Group ranks #999999 out of 392 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, SELLAS Life Sciences Group has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does SELLAS Life Sciences Group's EV-to-EBITDA compare to MBX and BHVN?
According to the Biotechnology industry distribution chart, SELLAS Life Sciences Group ranks #999999 out of 392 companies for EV-to-EBITDA. This places SELLAS Life Sciences Group in the lower half of its industry. The industry median EV-to-EBITDA is 12.94. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 12.94, based on 392 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on SELLAS Life Sciences Group. For the Biotechnology industry, the median EV-to-EBITDA is 12.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SELLAS Life Sciences Group's current EV-to-EBITDA is -76.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SELLAS Life Sciences Group stock overvalued right now?
SELLAS Life Sciences Group (SLS) has a current EV-to-EBITDA of -76.37. The current EV-to-EBITDA is -76.37. SELLAS Life Sciences Group's overall GF Score™ is 25/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For SELLAS Life Sciences Group (SLS), the current EV-to-EBITDA is -76.37 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
25GF Score
Get the complete analysis for SLS
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SLS has been successfully added to your 
